Base de dados : MEDLINE
Pesquisa : D02.241.081.018.487 [Categoria DeCS]
Referências encontradas : 3928 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 393 ir para página                         

  1 / 3928 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28612110
[Au] Autor:Yadav U; Anjaria KB; Nairy R; Shirsath KB; Desai UN; Chaurasia RK; Bhat NN; Sapra BK
[Ad] Endereço:Radiological Physics and Advisory Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
[Ti] Título:Differential killing and radio-modifying effects of iodoacetate in mammalian normal and cancer cells.
[So] Source:Radiat Environ Biophys;56(3):227-239, 2017 Aug.
[Is] ISSN:1432-2099
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:To explore possible applications of iodoacetate (IA), a glycolytic inhibitor, in cancer treatment, we screened its cytotoxicity and radioprotective/sensitizing efficacy in three different mammalian cell lines; A549 (human lung carcinoma), MCF7 (human mammary cancer), a non-cancerous CHO (Chinese hamster ovary) cells and human lymphocytes. Experiments were carried out using IA concentrations ranging from 0.01 to 2.5 µg/ml, with or without Coγ-radiation. In the outcomes, IA was found to exhibit higher toxicity in the cancer cells, whereas it was non-toxic/marginally toxic to the non-cancerous cells. Considerably higher glucose uptake in both cancer cells lines was observed indicating higher rates of glycolysis. IA significantly inhibited glycolysis as reflected by GAPDH activity inhibition. Radiomodifying effects of IA were found to be concentration dependent in both cancerous and non-cancerous cells. The response in non-cancerous was found to be biphasic: at lower concentrations, it offered significant radioprotection; however, the protection decreased with increasing concentration. Moreover, at the highest tested concentration, marginal radiosensitization was also observed (as indicated by clonogenic assay). In both cancer cells, IA offered significant amount of radiosensitization which was considerably high at higher concentrations. Further experiments were carried out to estimate the Dose Modification Factor (DMF) to quantify and compare relative radiosensitization by IA in cancer and normal cell lines. The DMF was calculated for three different concentrations of IA, 0.5, 1, and 1.5 µg/ml, and corresponding values were found to be 1.26, 1.43, and 1.89 for A549 cancer cells, whereas for normal CHO cells, it was 1.13, 1.13, and 1.24. In conclusion, differential killing and radiosensitizing effects of IA suggest that it may have potential use as a anticancer agent and radiosensitizer in cancer therapy.
[Mh] Termos MeSH primário: Iodoacetatos/farmacologia
Radiossensibilizantes/farmacologia
[Mh] Termos MeSH secundário: Animais
Transporte Biológico/efeitos dos fármacos
Transporte Biológico/efeitos da radiação
Células CHO
Morte Celular/efeitos dos fármacos
Morte Celular/efeitos da radiação
Linhagem Celular Tumoral
Cricetinae
Cricetulus
Relação Dose-Resposta a Droga
Glucose/metabolismo
Seres Humanos
Linfócitos/efeitos dos fármacos
Linfócitos/metabolismo
Linfócitos/efeitos da radiação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodoacetates); 0 (Radiation-Sensitizing Agents); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170615
[St] Status:MEDLINE
[do] DOI:10.1007/s00411-017-0699-0


  2 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594958
[Au] Autor:Yang Y; Wang Y; Kong Y; Zhang X; Bai L
[Ad] Endereço:Department of Orthopedic Surgery, Shengjing Hospital, China Medical University, ShenYang, Liaoning, China.
[Ti] Título:The effects of different frequency treadmill exercise on lipoxin A4 and articular cartilage degeneration in an experimental model of monosodium iodoacetate-induced osteoarthritis in rats.
[So] Source:PLoS One;12(6):e0179162, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The aim was to investigate the effects of different frequencies treadmill exercise with total exercise time being constancy on articular cartilage, lipoxin A4 (LXA4) and the NF-κB pathway in rat model of monosodium iodoacetate-induced osteoarthritis (OA). Fifty male Sprague-Dawley rats were randomly divided into five groups (n = 10): controls (CG), knee OA model (OAG), OA + treadmill exercise once daily (OAE1), OA + treadmill exercise twice daily, rest interval between exercise>4h (OAE2) and OA + treadmill exercise three times daily, rest interval between exercise>4h (OAE3). Rats were evaluated after completing the treadmill exercise program (speed, 18 m/min; total exercise time 60 min/day; 5 days/week for 8 weeks). Interleukin (IL)-1ß, tumor necrosis factor (TNF)-α, and LXA4 in serum and intra-articular lavage fluid were measured by ELISA. Changes in articular cartilage were evaluated by histology, immunohistochemistry, western blotting and quantitative real-time-PCR. LXA4 in the serum and intra-articular lavage fluid increased in all OAE groups, and histological evaluation indicated that the OAE3 group had the best treatment response. The expression of COL2A1 and IκB-ß in articular cartilage increased in all OAE groups vs the OAG group, whereas expression of IL-1ß, TNF-α, matrix metalloproteinase (MMP)-13, and NF-κB p65 was reduced in all OAE groups compared with the OAG. Under the condition of 60 min treadmill exercise with moderate-intensity, to fulfill in three times would have better chondroprotective effects than to fulfill in two or one time on monosodium iodoacetate-induced OA in rats. And it may be worked through the anti-inflammatory activity of LXA4 and the NF-κB pathway.
[Mh] Termos MeSH primário: Cartilagem Articular/metabolismo
Cartilagem Articular/patologia
Lipoxinas/metabolismo
Osteoartrite/induzido quimicamente
Osteoartrite/patologia
Condicionamento Físico Animal
[Mh] Termos MeSH secundário: Animais
Western Blotting
Modelos Animais de Doenças
Ensaio de Imunoadsorção Enzimática
Imuno-Histoquímica
Iodoacetatos
Articulações/patologia
Masculino
NF-kappa B/metabolismo
Osteoartrite/sangue
Reação em Cadeia da Polimerase
Ratos Sprague-Dawley
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodoacetates); 0 (Lipoxins); 0 (NF-kappa B); 0 (lipoxin A4)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179162


  3 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27916555
[Au] Autor:Kalinichev M; Donovan-Rodriguez T; Girard F; Haddouk H; Royer-Urios I; Schneider M; Bate ST; Marker C; Pomonis JD; Poli S
[Ad] Endereço:Addex Therapeutics SA, Chemin des Mines 9, CH-1202, Geneva, Switzerland. Electronic address: mikhail.kalinichev@ipsen.com.
[Ti] Título:ADX71943 and ADX71441, novel positive allosteric modulators of the GABA receptor with distinct central/peripheral profiles, show efficacy in the monosodium iodoacetate model of chronic osteoarthritis pain in the rat.
[So] Source:Eur J Pharmacol;795:43-49, 2017 Jan 15.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:We tested novel positive allosteric modulators (PAMs) of the γ-aminobutyric acid receptor B (GABA ), ADX71943 and ADX71441in the monosodium iodoacetate model of chronic osteoarthritis pain in rats with the objective to delineate the role of peripheral versus central GABA receptor populations in modulation of chronic pain. Anesthetized Sprague-Dawley rats received an injection of monosodium iodoacetate into the knee and were tested for hyperalgesia starting post-MIA day 14. Effects of compounds on ipsilateral joint compression threshold were evaluated on post-MIA day 14 (after acute treatment), as well as after repeated, daily treatment on days 21 and 28 (ADX71943 only) and were compared to those of celecoxib (30mg/kg, p.o.). The PAMs were also tested in the rat rotarod test for potential muscle-relaxant effects. Acutely, ADX71943 (1-30mg/kg, p.o.), the peripherally restricted PAM, resulted in similar increases in pain threshold across the doses on day 14, while showing reduced efficacy on day 21 and no efficacy on day 28. A clear reduction in the efficacy of celecoxib across testing was also noted in this experiment. Acutely ADX71441 (0.3-15mg/kg, p.o.), the central-peripheral PAM, resulted in over 2-fold increases in pain threshold at 15mg/kg (but not at lower doses) on day 14, while causing more modest effects on day 21. Celecoxib increased pain threshold after both acute and daily treatment, showing overall similar efficacy. Thus, early, presumably more inflammatory phase of osteoarthritis pain in more sensitive to GABA PAMs with peripherally restricted profile, while later, presumably more neuropathic phase is more sensitive to PAMs with central-peripheral profile.
[Mh] Termos MeSH primário: Proteínas de Bactérias/farmacologia
Dor Crônica/complicações
Dor Crônica/tratamento farmacológico
Iodoacetatos/farmacologia
Osteoartrite/complicações
Receptores de GABA-B/metabolismo
Fatores de Transcrição/farmacologia
[Mh] Termos MeSH secundário: Regulação Alostérica/efeitos dos fármacos
Animais
Proteínas de Bactérias/uso terapêutico
Dor Crônica/induzido quimicamente
Dor Crônica/metabolismo
Relação Dose-Resposta a Droga
Hiperalgesia/complicações
Hiperalgesia/tratamento farmacológico
Masculino
Limiar da Dor/efeitos dos fármacos
Ratos
Ratos Sprague-Dawley
Teste de Desempenho do Rota-Rod
Fatores de Transcrição/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ADX71441); 0 (ADX71943); 0 (Bacterial Proteins); 0 (Iodoacetates); 0 (Receptors, GABA-B); 0 (Transcription Factors)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170508
[Lr] Data última revisão:
170508
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161206
[St] Status:MEDLINE


  4 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27735054
[Au] Autor:Forte N; Medrihan L; Cappetti B; Baldelli P; Benfenati F
[Ad] Endereço:Center for Synaptic Neuroscience and Technology, Istituto Italiano di Tecnologia, Genova, Italy.
[Ti] Título:2-Deoxy-d-glucose enhances tonic inhibition through the neurosteroid-mediated activation of extrasynaptic GABA receptors.
[So] Source:Epilepsia;57(12):1987-2000, 2016 Dec.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The inhibition of glycolysis exerts potent antiseizure effects, as demonstrated by the efficacy of ketogenic and low-glucose/nonketogenic diets in the treatment of drug-resistant epilepsy. ATP-sensitive potassium (K ) channels have been initially identified as the main determinant of the reduction of neuronal hyperexcitability. However, a plethora of other mechanisms have been proposed. Herein, we report the ability of 2-deoxy-d-glucose (2-DG), a glucose analog that inhibits glycolytic enzymes, of potentiating γ-aminobutyric acid (GABA)ergic tonic inhibition via neurosteroid-mediated activation of extrasynaptic GABA receptors. METHODS: Acute effects of 2-DG on the ATP-sensitive potassium currents, GABAergic tonic inhibition, firing activity, and interictal events were assessed in hippocampal slices by whole-cell patch-clamp and local field potential recordings of dentate gyrus granule cells. RESULTS: Acute application of 2-DG activates two distinct outward conductances: a K channel-mediated current and a bicuculline-sensitive tonic current. The effect of 2-DG on such GABAergic tonic currents was fully prevented by either finasteride or PK11195, which are specific inhibitors of the neurosteroidogenesis pathway acting via different mechanisms. Moreover, the oxidized form of vitamin C, dehydroascorbic acid, known for its ability to induce neurosteroidogenesis, also activated a bicuculline-sensitive tonic current in a manner indistinguishable from that of 2-DG. Finally, we found that the enhancement of K current by 2-DG primarily regulates intrinsic firing rate of granule cells, whereas the increase of the GABAergic tonic current plays a key role in reducing the frequency of interictal events evoked by treatment of hippocampal slices with the convulsive agent 4-aminopyridine. SIGNIFICANCE: We demonstrated, for the first time, that 2-DG potentiates the extrasynaptic tonic GABAergic current through activation of neurosteroidogenesis. Such tonic inhibition represents the main conductance responsible for the antiseizure action of this glycolytic inhibitor.
[Mh] Termos MeSH primário: Antimetabólitos/farmacologia
Desoxiglucose/farmacologia
Inibição Neural/efeitos dos fármacos
Neurônios/efeitos dos fármacos
Receptores de GABA/metabolismo
[Mh] Termos MeSH secundário: 4-Aminopiridina/farmacologia
Animais
Antineoplásicos/farmacologia
Bicuculina/farmacologia
Inibidores Enzimáticos/farmacologia
Feminino
Finasterida/farmacologia
Antagonistas de Receptores de GABA-A/farmacologia
Glibureto/farmacologia
Hipocampo/citologia
Hipoglicemiantes/farmacologia
Técnicas In Vitro
Iodoacetatos/farmacologia
Isoquinolinas/farmacologia
Masculino
Potenciais da Membrana/efeitos dos fármacos
Camundongos
Camundongos Endogâmicos C57BL
Bloqueadores dos Canais de Potássio/farmacologia
Estatísticas não Paramétricas
Ácido gama-Aminobutírico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antimetabolites); 0 (Antineoplastic Agents); 0 (Bzrp protein, mouse); 0 (Enzyme Inhibitors); 0 (GABA-A Receptor Antagonists); 0 (Hypoglycemic Agents); 0 (Iodoacetates); 0 (Isoquinolines); 0 (Potassium Channel Blockers); 0 (Receptors, GABA); 56-12-2 (gamma-Aminobutyric Acid); 57GNO57U7G (Finasteride); 9G2MP84A8W (Deoxyglucose); BH3B64OKL9 (4-Aminopyridine); SX6K58TVWC (Glyburide); Y37615DVKC (Bicuculline); YNF83VN1RL (PK 11195)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161014
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13578


  5 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27484345
[Au] Autor:Wang ZM; Chen YC; Wang DP
[Ad] Endereço:Department of Bone and Hand Microsurgery, Shandong Wendeng Orthopedic and Traumatic Hospital, Shandong, China.
[Ti] Título:Resveratrol, a natural antioxidant, protects monosodium iodoacetate-induced osteoarthritic pain in rats.
[So] Source:Biomed Pharmacother;83:763-770, 2016 Oct.
[Is] ISSN:1950-6007
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Osteoarthritis (OA) is a chronic progressive joint disease characterized by advanced joint pain, subchondral bone sclerosis and articular cartilage degeneration. Resveratrol has been shown to have anti-inflammatory, cardioprotective and antioxidant properties and to inhibit platelet aggregation and coagulation. However, the effects of resveratrol on OA have not been examined. In this study, we investigate the protective effects of resveratrol on monosodium iodoacetate (MIA)-induced OA through inhibition of cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS) signaling pathway in a rat model. METHODS: A single intra-articular injection of MIA was injected into rats for the induction of OA. The mechanical, heat and cold hyperalgesia were measured at days 0, 7 and 14. The serum and synovial fluid levels of IL-1ß, IL-10 and TNF-α and osteocalcin were measured by enzyme-linked immunosorbent assay. The mRNA and protein expressions of IL-1ß, IL-10, TNF-α, Il-6, MMP-13 and COX-2 and iNOS were determined by RT-PCR and western blot, respectively. Osteoarthritic lesion in the knee joint was evaluated by histological analysis. RESULTS: MIA-injected rats treated with resveratrol at a dose of either 5 or 10mg/kg body weight were significantly reduced hyperalgesia of mechanical, heat and cold and increased the vertical and horizontal movements. Subsequently, MIA-injected rats increased serum and synovial fluid levels of IL-1ß, IL-10, IL-6, TNF-α, MMP-13 and osteoclastic activity marker, osteocalcin and its articular cartilage mRNA and protein expressions. Further, MIA-injected rats increased COX-2 and iNOS mRNA and protein expressions were decreased by resveratrol. The protective effect of resveratrol was comparable to a reference drug, etoricoxib. The cartilage damage induced by MIA were attenuated by resveratrol. CONCLUSIONS: Taken together, resveratrol has the potential to improve MIA-induced cartilage damage by inhibiting the levels and expressions of inflammatory mediators suggesting that resveratrol may be a potential therapeutic agent for OA.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Osteoartrite/tratamento farmacológico
Osteoartrite/prevenção & controle
Dor/tratamento farmacológico
Dor/prevenção & controle
Estilbenos/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Antioxidantes/farmacologia
Cartilagem Articular/efeitos dos fármacos
Cartilagem Articular/patologia
Ciclo-Oxigenase 2/genética
Ciclo-Oxigenase 2/metabolismo
Citocinas/sangue
Citocinas/genética
Extremidades/patologia
Hiperalgesia/sangue
Hiperalgesia/complicações
Hiperalgesia/tratamento farmacológico
Iodoacetatos
Masculino
Óxido Nítrico Sintase Tipo II/metabolismo
Osteoartrite/sangue
Osteoartrite/induzido quimicamente
Dor/sangue
Dor/induzido quimicamente
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Ratos Sprague-Dawley
Estilbenos/farmacologia
Líquido Sinovial/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Cytokines); 0 (Iodoacetates); 0 (RNA, Messenger); 0 (Stilbenes); EC 1.14.13.39 (Nitric Oxide Synthase Type II); EC 1.14.99.1 (Cyclooxygenase 2); Q369O8926L (resveratrol)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160804
[St] Status:MEDLINE


  6 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27068285
[Au] Autor:Abaei M; Sagar DR; Stockley EG; Spicer CH; Prior M; Chapman V; Auer DP
[Ad] Endereço:Radiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
[Ti] Título:Neural correlates of hyperalgesia in the monosodium iodoacetate model of osteoarthritis pain.
[So] Source:Mol Pain;12, 2016.
[Is] ISSN:1744-8069
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The mechanisms driving osteoarthritic pain remain poorly understood, but there is increasing evidence for a role of the central nervous system in the chronification of pain. We used functional magnetic resonance imaging to investigate the influence of a model of unilateral knee osteoarthritis on nociceptive processing. RESULTS: Four to five weeks post intra-articular injection of monosodium iodoacetate (MIA, 1 mg) into the left knee, Sprague Dawley rats were anesthetized for functional magnetic resonance imaging studies to characterize the neural response to a noxious stimulus (intra-articular capsaicin injection). In a two-arm cross-over design, 5 µM/50 µl capsaicin was injected into either the left knee (n = 8, CAPS-MIA) or right control knee (n = 8, CAPS-CON), preceded by contralateral vehicle (SAL) injection. To assess neural correlates of mechanical hyperalgesia, hindpaws were stimulated with von Frey hairs (8 g: MIA; 15 g: control knee, based on behavioral withdrawal responses). The CAPS-MIA group exhibited significant activation of the periaqueductal gray, unilateral thalamus and bilateral mensencephalon, superior-colliculus, and hippocampus, with no significant activation in the other groups/conditions. Capsaicin injection increased functional connectivity in the mid-brain network and mediodorsal thalamic nucleus, hippocampus, and globus pallidus, which was significantly stronger in CAPS-MIA compared to CAPS-CON groups. Mechanical stimulation of the hyperalgesic (ipsilateral to MIA knee) and normalgesic (contralateral) hindpaws evoked qualitatively different brain activation with more widespread brainstem and anterior cingulate (ACC) activation when stimulating the hyperalgesic paw, and clearer frontal sensory activation from the normalgesic paw. CONCLUSIONS: We provide evidence for modulation of nociceptive processing in a chronic knee osteoarthritis pain model with stronger brain activation and alteration of brain networks induced by the pro-nociceptive stimulus. We also report a shift to a medial pain activation pattern following stimulation of the hyperalgesic hindpaw. Taken together, our data support altered neural pain processing as a result of peripheral and central pain sensitization in this model.
[Mh] Termos MeSH primário: Encéfalo/patologia
Hiperalgesia/complicações
Hiperalgesia/tratamento farmacológico
Iodoacetatos/uso terapêutico
Ácido Iodoacético/uso terapêutico
Osteoartrite do Joelho/tratamento farmacológico
Dor/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Comportamento Animal
Encéfalo/efeitos dos fármacos
Mapeamento Encefálico
Capsaicina
Modelos Animais de Doenças
Estimulação Elétrica
Hiperalgesia/patologia
Hiperalgesia/fisiopatologia
Injeções Intra-Articulares
Iodoacetatos/farmacologia
Ácido Iodoacético/farmacologia
Imagem por Ressonância Magnética
Nociceptividade/efeitos dos fármacos
Osteoartrite do Joelho/complicações
Osteoartrite do Joelho/fisiopatologia
Dor/complicações
Dor/fisiopatologia
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Iodoacetates); S07O44R1ZM (Capsaicin); WF5188V710 (Iodoacetic Acid)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160413
[St] Status:MEDLINE


  7 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26197088
[Au] Autor:Lee DG; Park SY; Chung WS; Park JH; Hwang E; Mavlonov GT; Kim IH; Kim KY; Yi TH
[Ad] Endereço:1 Department of Oriental Medicinal Materials & Processing, College of Life Science, Kyung Hee University , Gyeonggi-do, Korea.
[Ti] Título:Fucoidan Prevents the Progression of Osteoarthritis in Rats.
[So] Source:J Med Food;18(9):1032-41, 2015 Sep.
[Is] ISSN:1557-7600
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study investigated the effects of fucoidan (extract from Hizikia fusiforme) on symptoms and inflammatory cytokine activation in rats with monosodium iodoacetate (MIA)-induced osteoarthritis (OA). Forty male SD rats were divided into five groups, including normal, negative control (MIA), positive control (Lyprinol), and two experimental groups treated with 50 or 100 mg/kg fucoidan. Weight-bearing assessments were done after MIA injection into the right knee to induce OA. After 14 days of treatment, microcomputed tomographic (micro-CT) images were made of rat knee joints, and then animals were sacrificed for joint histology and inflammatory cytokine level assessments. MIA injection successfully induced OA by causing 40% weight-bearing imbalance, severe bone loss and cartilage degeneration, and markedly increased cytokine levels. However, fucoidan groups showed over 45% of imbalance and no articular cartilage surface lesions or change in subchondral trabecular bones in Micro-CT images. Histological analysis revealed that cartilage morphology and cell counts were also normal in the 100 mg/kg fucoidan group. In addition, the 100 mg/kg fucoidan groups exhibited lower serum tumor necrosis factor alpha (TNF-α) (30%), interleukin 1 beta (IL-1ß) (48%), and matrix metalloproteinase-1 (MMP-1) (65%) compared to the MIA groups. These results suggest that administration of fucoidan prevents the progression of OA in a MIA-induced OA rat model.
[Mh] Termos MeSH primário: Artrite Experimental/tratamento farmacológico
Cartilagem Articular/efeitos dos fármacos
Osteoartrite do Joelho/tratamento farmacológico
Polissacarídeos/uso terapêutico
Sargassum/química
[Mh] Termos MeSH secundário: Animais
Artrite Experimental/metabolismo
Artrite Experimental/patologia
Osso e Ossos/efeitos dos fármacos
Doenças das Cartilagens/prevenção & controle
Cartilagem Articular/patologia
Modelos Animais de Doenças
Progressão da Doença
Interleucina-1beta/metabolismo
Iodoacetatos
Articulação do Joelho/efeitos dos fármacos
Articulação do Joelho/metabolismo
Articulação do Joelho/patologia
Masculino
Metaloproteinase 1 da Matriz/metabolismo
Osteoartrite do Joelho/metabolismo
Osteoartrite do Joelho/patologia
Fitoterapia
Extratos Vegetais/farmacologia
Extratos Vegetais/uso terapêutico
Polissacarídeos/farmacologia
Ratos Sprague-Dawley
Fator de Necrose Tumoral alfa/metabolismo
Microtomografia por Raio-X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Interleukin-1beta); 0 (Iodoacetates); 0 (Plant Extracts); 0 (Polysaccharides); 0 (Tumor Necrosis Factor-alpha); 9072-19-9 (fucoidan); EC 3.4.24.7 (MMP1 protein, rat); EC 3.4.24.7 (Matrix Metalloproteinase 1)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150722
[St] Status:MEDLINE
[do] DOI:10.1089/jmf.2014.3334


  8 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26187762
[Au] Autor:Cardador MJ; Fernández-Salguero J; Gallego M
[Ad] Endereço:Department of Analytical Chemistry, Campus of Rabanales, University of Córdoba, E-14071 Córdoba, Spain.
[Ti] Título:Simultaneous quantification of trihalomethanes and haloacetic acids in cheese by on-line static headspace gas chromatography-mass spectrometry.
[So] Source:J Chromatogr A;1408:22-9, 2015 Aug 21.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Trihalomethanes (THMs) and haloacetic acids (HAAs) are the two most prevalent classes of disinfection by-products (DBPs) that are present in treated water. Four THMs and six HAAs are regulated by several countries in drinking waters but no regulation for these DBPs has been established in foods. THMs are volatile species that can easily be determined by static headspace (SHS)-GC-MS, but HAAs require a derivatisation step to make them suitable for GC due to their polar and hydrophilic nature. This paper describes the first analytical method that performs the simultaneous determination of 10 THMs and 13 HAAs (chlorinated, brominated and iodinated) in cheeses by SHS in one unique GC-MS run. Parameters controlling leaching, centrifugation, derivatisation and volatilisation were optimised taking into account the high volatility of THMs and the thermal instability of HAAs. To increase sensitivity, 3g of cheese was extracted with 10mL of water at pH 4.5-7.7, and after centrifugation the supernatant (∼8mL) was introduced into an HS vial for the derivatisation (HAAs) and volatilisation (HAA esters and THMs) of the species in an automatic SHS unit coupled to GC-MS. Detection limits within the range of 0.05-0.50 and 0.15-0.85µg/kg for THMs and HAAs, respectively, were obtained, and the relative standard deviation was lower than 10% for all the target analytes. Recoveries throughout the whole method were between 85-90% and 92-97% for THMs and HAAs, respectively. The SHS-GC-MS method was applied for the determination of THMs and HAAs in 3 groups of Spanish cheeses, which can be contaminated through contact with treated water during the manufacturing steps. Up to 2 THMs and 4 HAAs were found at µg/kg levels in the samples analysed.
[Mh] Termos MeSH primário: Acetatos/análise
Queijo/análise
Trialometanos/análise
Poluentes Químicos da Água/análise
[Mh] Termos MeSH secundário: Cloroacetatos/análise
Desinfecção
Fluoracetatos/análise
Cromatografia Gasosa-Espectrometria de Massas
Iodoacetatos/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acetates); 0 (Chloroacetates); 0 (Fluoroacetates); 0 (Iodoacetates); 0 (Trihalomethanes); 0 (Water Pollutants, Chemical); 68-10-0 (bromoacetate)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150803
[Lr] Data última revisão:
150803
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150719
[St] Status:MEDLINE


  9 / 3928 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26112847
[Au] Autor:Kumari RR; More AS; Gupta G; Lingaraju MC; Balaganur V; Kumar P; Kumar D; Sharma AK; Mishra SK; Tandan SK
[Ti] Título:Effect of alcoholic extract of Entada pursaetha DC on monosodium iodoacetate-induced osteoarthritis pain in rats.
[So] Source:Indian J Med Res;141(4):454-62, 2015 Apr.
[Is] ISSN:0971-5916
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & OBJECTIVES: Osteoarthritis (OA) is a degenerative disease characterized by joint pain and progressive loss of articular cartilage. Entada pursaetha has been traditionally used in the treatment of inflammatory disease, liver ailment, etc. In this study we investigated suppressive effect of ethanolic extract of E. pursaetha (EPE) on monosodium iodoacetate (MIA)-induced osteoarthritis pain and disease progression by histopathological changes in joints in a rat model. METHODS: OA was induced in right knee of rat by intra-articular injection of 3 mg of MIA and characterized by pathological progression of disease and pain of affected joint. Spontaneous movements, mechanical, thermal and cold sensitivity were monitored at days 0 (before drug and MIA injection), 7, 14 and 21 of MIA administration. EPE (30, 100 and 300 mg/kg), vehicle or etoricoxib (10 mg/ kg; reference drug) were administered daily for 21 days by oral route. RESULTS: EPE at various doses significantly reduced mechanical, heat, cold hyperalgesia and increased the horizontal and vertical movements in intra-articular MIA injected rats. EPE prevented the damage to cartilage structure and reduced the cellular abnormalities. Articular cartilage of rats treated with EPE at 300 mg/kg group was almost normal with well-developed smooth surface and chondrocytes were distributed individually or arranged in column. INTERPRETATION & CONCLUSIONS: The present findings showed that the EPE was not only able to mitigate pain and hyperalgesia but also inhibited MIA-induced cartilage degeneration in vivo. EPE may have the potential to become therapeutic modality in the treatment of osteoarthritis. However, further studies need to be done to confirm these findings in other models and clinical trials.
[Mh] Termos MeSH primário: Artrite Experimental/tratamento farmacológico
Osteoartrite/tratamento farmacológico
Dor/tratamento farmacológico
Extratos Vegetais/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Artrite Experimental/induzido quimicamente
Artrite Experimental/patologia
Cartilagem Articular/efeitos dos fármacos
Condrócitos/efeitos dos fármacos
Modelos Animais de Doenças
Fabaceae/química
Seres Humanos
Injeções Intra-Articulares
Iodoacetatos/toxicidade
Masculino
Osteoartrite/induzido quimicamente
Osteoartrite/patologia
Dor/patologia
Extratos Vegetais/química
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Iodoacetates); 0 (Plant Extracts)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150627
[St] Status:MEDLINE
[do] DOI:10.4103/0971-5916.159296


  10 / 3928 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26067584
[Au] Autor:La Porta C; Bura SA; Llorente-Onaindia J; Pastor A; Navarrete F; García-Gutiérrez MS; De la Torre R; Manzanares J; Monfort J; Maldonado R
[Ad] Endereço:aLaboratory of Neuropharmacology, Department of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain bDepartment of Experimental and Health Sciences, Pompeu Fabra University (CEXS-UPF), Barcelona, Spain cCell Research Group on Inflammation and Cartilage, Hospital del Mar Medical Research Institute, Rheumatology Department, Hospital del Mar, Barcelona, Spain dHuman Pharmacology and Clinical Neurosciences Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain eDepartment of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain fInstituto de Neurociencias, Universidad Miguel Hernández-CSIC, Alicante, Spain gCIBER de Fisiopatología Obesidad y Nutrición, Santiago de Compostela, Spain hDepartment of Rheumatology, Universitat Autònoma de Barcelona, Hospital del Mar, Barcelona, Spain (A. S. Bura is now with the Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, München, Germany).
[Ti] Título:Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain.
[So] Source:Pain;156(10):2001-12, 2015 Oct.
[Is] ISSN:1872-6623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, we investigated the role of the endocannabinoid system (ECS) in the emotional and cognitive alterations associated with osteoarthritis pain. The monosodium iodoacetate model was used to evaluate the affective and cognitive manifestations of osteoarthritis pain in type 1 (CB1R) and type 2 (CB2R) cannabinoid receptor knockout and wild-type mice and the ability of CB1R (ACEA) and CB2R (JWH133) selective agonists to improve these manifestations during a 3-week time period. The levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were measured in plasma and brain areas involved in the control of these manifestations. Patients with knee osteoarthritis and healthy controls were recruited to evaluate pain, affective, and cognitive symptoms, as well as plasma endocannabinoid levels and cannabinoid receptor gene expression in peripheral blood lymphocytes. The affective manifestations of osteoarthritis were enhanced in CB1R knockout mice and absent in CB2R knockouts. Interestingly, both ACEA and JWH133 ameliorated the nociceptive and affective alterations, whereas ACEA also improved the associated memory impairment. An increase of 2-AG levels in prefrontal cortex and plasma was observed in this mouse model of osteoarthritis. In agreement, an increase of 2-AG plasmatic levels and an upregulation of CB1R and CB2R gene expression in peripheral blood lymphocytes were observed in patients with osteoarthritis compared with healthy subjects. Changes found in these biomarkers of the ECS correlated with pain, affective, and cognitive symptoms in these patients. The ECS plays a crucial role in osteoarthritis and represents an interesting pharmacological target and biomarker of this disease.
[Mh] Termos MeSH primário: Transtornos Cognitivos/etiologia
Endocanabinoides/metabolismo
Transtornos do Humor/etiologia
Osteoartrite/complicações
[Mh] Termos MeSH secundário: Idoso
Animais
Ácidos Araquidônicos/metabolismo
Ácidos Araquidônicos/uso terapêutico
Transtornos Cognitivos/tratamento farmacológico
Hormônio Liberador da Corticotropina/genética
Hormônio Liberador da Corticotropina/metabolismo
Endocanabinoides/genética
Endocanabinoides/uso terapêutico
Inibidores Enzimáticos/toxicidade
Feminino
Glicerídeos/metabolismo
Glicerídeos/uso terapêutico
Seres Humanos
Iodoacetatos/toxicidade
Masculino
Aprendizagem em Labirinto/efeitos dos fármacos
Aprendizagem em Labirinto/fisiologia
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Meia-Idade
Transtornos do Humor/diagnóstico
Transtornos do Humor/tratamento farmacológico
Transtornos do Humor/genética
Osteoartrite/induzido quimicamente
Osteoartrite/genética
Córtex Pré-Frontal/efeitos dos fármacos
Córtex Pré-Frontal/metabolismo
Receptor CB1 de Canabinoide/deficiência
Receptor CB1 de Canabinoide/genética
Receptor CB2 de Canabinoide/deficiência
Receptor CB2 de Canabinoide/genética
Receptores de Glucocorticoides/genética
Receptores de Glucocorticoides/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Arachidonic Acids); 0 (Endocannabinoids); 0 (Enzyme Inhibitors); 0 (Glycerides); 0 (Iodoacetates); 0 (Receptor, Cannabinoid, CB1); 0 (Receptor, Cannabinoid, CB2); 0 (Receptors, Glucocorticoid); 8D239QDW64 (glyceryl 2-arachidonate); 9015-71-8 (Corticotropin-Releasing Hormone)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150613
[St] Status:MEDLINE
[do] DOI:10.1097/j.pain.0000000000000260



página 1 de 393 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde